PTC Therapeutics reports Q4 Sephience revenue of $92.5 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil falls over 4% as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
January 12, 2026 8:30 AM ESTStrong Sephience (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M
Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance
2026 product revenue guidance of $700 800M, representing 19 36% year-over-year growth
Strong cash position of approximately $1.94B as of December 31
WARREN, N.J., Jan. 12, 2026 /PRNewswire/ --Â PTC... More
